Literature DB >> 19075488

Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles.

Yuusuke Konno1, Kenjiro Kimura.   

Abstract

Cilnidipine is a dihydropyridine calcium channel blocker that acts on both L-type and N-type calcium channels. The effects of cilnidipine given intravenously at doses of 2.5, 5.0, and 10 microg/kg were studied using an ex vivo hydronephrosis model in spontaneously hypertensive rats. The effects of nifedipine at a dose of 10 microg/kg were also studied using the same model as a reference. Cilnidipine caused dose-dependent blood pressure reduction and dilatation of the glomerular afferent arterioles; the arteriolar diameter after cilnidipine infusion at 2.5, 5.0, and 10 microg/kg was 101% +/- 3%, 112% +/- 4%, and 123% +/- 6% relative to baseline, respectively. With cilnidipine, dilatation of the efferent arterioles was also observed; it was maximal after 5 to 10 minutes. Five minutes after administration of 2.5, 5.0, and 10 microg/kg of cilnidipine, the efferent arteriolar diameter was 103% +/- 2%, 109% +/- 4%, and 119% +/- 4% of baseline, respectively. This efferent arteriolar dilating action of cilnidipine was abolished after pretreatment with omega-conotoxin, a selective N-type calcium channel blocker. A dose-dependent increase of glomerular blood flow volume was also observed after cilnidipine infusion. Nifedipine, an L-type calcium channel blocker, at a dose of 10 microg/kg reduced systolic blood pressure to a similar extent as cilnidipine at a dose of 10 microg/kg, but only dilated the afferent arterioles and had no significant effect on efferent arterioles. Cilnidipine dilated both the afferent and efferent glomerular arterioles. The efferent arteriolar dilating effect of cilnidipine may be attributed to its inhibition of the N-type calcium channel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075488     DOI: 10.1536/ihj.49.723

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  14 in total

1.  Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.

Authors:  Yu-Yan Fan; Masakazu Kohno; Daisuke Nakano; Hiroyuki Ohsaki; Hiroyuki Kobori; Diah Suwarni; Naro Ohashi; Hirofumi Hitomi; Katsuhiko Asanuma; Takahisa Noma; Yasuhiko Tomino; Toshiro Fujita; Akira Nishiyama
Journal:  J Hypertens       Date:  2010-05       Impact factor: 4.844

Review 2.  Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.

Authors:  Nicole Leung; Kevin Yip; Michael H Pillinger; Michael Toprover
Journal:  Mayo Clin Proc       Date:  2022-07       Impact factor: 11.104

3.  Drug off-target effects predicted using structural analysis in the context of a metabolic network model.

Authors:  Roger L Chang; Li Xie; Lei Xie; Philip E Bourne; Bernhard Ø Palsson
Journal:  PLoS Comput Biol       Date:  2010-09-23       Impact factor: 4.475

4.  L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.

Authors:  Masanori Abe; Noriaki Maruyama; Hiroko Suzuki; Atsushi Inoshita; Yoshinori Yoshida; Kazuyoshi Okada; Masayoshi Soma
Journal:  Heart Vessels       Date:  2012-08-23       Impact factor: 2.037

5.  N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

Authors:  Bai Lei; Daisuke Nakano; Yoshihide Fujisawa; Ya Liu; Hirofumi Hitomi; Hiroyuki Kobori; Hirohito Mori; Tsutomu Masaki; Katsuhiko Asanuma; Yasuhiko Tomino; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2012-07-21       Impact factor: 3.337

Review 6.  Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.

Authors:  Rosalie A Scholtes; Michaël J B van Baar; Megan D Kok; Petter Bjornstad; David Z I Cherney; Jaap A Joles; Daniël H van Raalte
Journal:  Nephrology (Carlton)       Date:  2021-01-04       Impact factor: 2.506

7.  Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study.

Authors:  Hiroko Abe; Tomoya Mita; Risako Yamamoto; Koji Komiya; Minako Kawaguchi; Yuko Sakurai; Tomoaki Shimizu; Chie Ohmura; Fuki Ikeda; Ryuzo Kawamori; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2012-10-22       Impact factor: 4.232

8.  Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure.

Authors:  Shoko Ohno; Hideki Yokoi; Kiyoshi Mori; Masato Kasahara; Koichiro Kuwahara; Junji Fujikura; Masaki Naito; Takashige Kuwabara; Hirotaka Imamaki; Akira Ishii; Moin A Saleem; Tomohiro Numata; Yasuo Mori; Kazuwa Nakao; Motoko Yanagita; Masashi Mukoyama
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

9.  Excellent tolerance to cilnidipine in hypertensives with amlodipine - induced edema.

Authors:  Ranjan Shetty; G Vivek; Kushal Naha; Anil Tumkur; Abhinav Raj; K L Bairy
Journal:  N Am J Med Sci       Date:  2013-01

10.  Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.

Authors:  Katsuayuki Ando; Kenji Ueshima; Sachiko Tanaka; Shinji Kosugi; Tosiya Sato; Hiroaki Matsuoka; Kazuwa Nakao; Toshiro Fujita
Journal:  Int J Med Sci       Date:  2013-07-30       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.